Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313360198> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W4313360198 endingPage "75.3" @default.
- W4313360198 startingPage "75.3" @default.
- W4313360198 abstract "Abstract Novel effective vaccines are key to solving many global health problems. Past efforts to rationally design vaccines that elicit strong cell-mediated responses have largely failed. Vaccine adjuvants, particularly toll-like receptor (TLR) agonists, are a promising tool to shape immune responses by polarizing CD4 T cells to distinct fates. Use of these adjuvants to design novel vaccines requires the full characterization of their effects on CD4 T cell differentiation, particularly in regard to the route of vaccination. In a large scale in vitro screen of vaccine adjuvants, we demonstrated that Pam3CSK4, a synthetic mimic of bacterial lipoproteins with TLR1/2 agonist activity, strongly polarized CD4 T cells to the Th1 fate (IFN-γ+, T-bet+) supporting cell-mediated responses. We adapted a vaccination system to study CD4 T cell polarization in vivo using ovalbumin-specific transgenic CD4 T cells. This in vivo system showed a route-specific effect, with strong Th1 responses from intravenous immunization with ovalbumin plus Pam3CSK4, but a lack of Th1 responses with immunization through more clinically relevant cutaneous routes. Interestingly, Pam3CSK4 in combination with a known Th1 polarizing adjuvant, CpG ODN, showed little to no Th1 response suggesting a dominant suppressive mechanism. Furthermore, suppression of Th1 differentiation occurred in response to both TLR1/2 and TLR6/2 agonists. Using a variety of cell-ablative mouse models we were able to reverse suppression of Th1 responses and identify specific candidates of innate immune cells mediating suppression during vaccination with TLR2 agonists. Current work focuses on mechanisms of suppression by TLR2 agonists in the skin and relevance to improving vaccine design." @default.
- W4313360198 created "2023-01-06" @default.
- W4313360198 creator A5000442561 @default.
- W4313360198 creator A5016158429 @default.
- W4313360198 creator A5044158194 @default.
- W4313360198 creator A5060217976 @default.
- W4313360198 date "2016-05-01" @default.
- W4313360198 modified "2023-09-27" @default.
- W4313360198 title "Cutaneous vaccination with TLR2 agonists results in the suppression of Th1 responses" @default.
- W4313360198 doi "https://doi.org/10.4049/jimmunol.196.supp.75.3" @default.
- W4313360198 hasPublicationYear "2016" @default.
- W4313360198 type Work @default.
- W4313360198 citedByCount "0" @default.
- W4313360198 crossrefType "journal-article" @default.
- W4313360198 hasAuthorship W4313360198A5000442561 @default.
- W4313360198 hasAuthorship W4313360198A5016158429 @default.
- W4313360198 hasAuthorship W4313360198A5044158194 @default.
- W4313360198 hasAuthorship W4313360198A5060217976 @default.
- W4313360198 hasConcept C126322002 @default.
- W4313360198 hasConcept C136449434 @default.
- W4313360198 hasConcept C170493617 @default.
- W4313360198 hasConcept C203014093 @default.
- W4313360198 hasConcept C22070199 @default.
- W4313360198 hasConcept C2776090121 @default.
- W4313360198 hasConcept C2776946954 @default.
- W4313360198 hasConcept C2777863537 @default.
- W4313360198 hasConcept C2778938600 @default.
- W4313360198 hasConcept C2780801004 @default.
- W4313360198 hasConcept C2781236682 @default.
- W4313360198 hasConcept C71924100 @default.
- W4313360198 hasConcept C86803240 @default.
- W4313360198 hasConcept C8891405 @default.
- W4313360198 hasConceptScore W4313360198C126322002 @default.
- W4313360198 hasConceptScore W4313360198C136449434 @default.
- W4313360198 hasConceptScore W4313360198C170493617 @default.
- W4313360198 hasConceptScore W4313360198C203014093 @default.
- W4313360198 hasConceptScore W4313360198C22070199 @default.
- W4313360198 hasConceptScore W4313360198C2776090121 @default.
- W4313360198 hasConceptScore W4313360198C2776946954 @default.
- W4313360198 hasConceptScore W4313360198C2777863537 @default.
- W4313360198 hasConceptScore W4313360198C2778938600 @default.
- W4313360198 hasConceptScore W4313360198C2780801004 @default.
- W4313360198 hasConceptScore W4313360198C2781236682 @default.
- W4313360198 hasConceptScore W4313360198C71924100 @default.
- W4313360198 hasConceptScore W4313360198C86803240 @default.
- W4313360198 hasConceptScore W4313360198C8891405 @default.
- W4313360198 hasIssue "1_Supplement" @default.
- W4313360198 hasLocation W43133601981 @default.
- W4313360198 hasOpenAccess W4313360198 @default.
- W4313360198 hasPrimaryLocation W43133601981 @default.
- W4313360198 hasRelatedWork W2034211073 @default.
- W4313360198 hasRelatedWork W2073312739 @default.
- W4313360198 hasRelatedWork W2133265454 @default.
- W4313360198 hasRelatedWork W2171475287 @default.
- W4313360198 hasRelatedWork W2205292570 @default.
- W4313360198 hasRelatedWork W2766011811 @default.
- W4313360198 hasRelatedWork W2772568294 @default.
- W4313360198 hasRelatedWork W31129911 @default.
- W4313360198 hasRelatedWork W336771203 @default.
- W4313360198 hasRelatedWork W4283693854 @default.
- W4313360198 hasVolume "196" @default.
- W4313360198 isParatext "false" @default.
- W4313360198 isRetracted "false" @default.
- W4313360198 workType "article" @default.